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Thrombolytic treatment with plasmin or plasminogen acti-
vators is meant to lyse thrombi and to recanalize a blood
vessel or catheter. The target thrombus can emerge in differ-
ent locations such as the deep veins of the leg (leading to deep
venous thrombosis), in the lung artery (pulmonary embo-
lism), and in arteries in the heart, brain (stroke), or leg, and
can block bypass grafts or dialysis catheters.
The target thrombi can be of different composition and
age, as documented in samples obtained by thrombectomy.
With myocardial infarction (MI), it has been reported that
nearly 50% of thrombi are older than 24 hours,1 and it has
been described that 9% of thrombi are older than 5 days.2 This
implies a quite wide spectrum in the composition of thrombi
and a reduced accessibility when reendothelialization has
progressed in the presence of matured thrombi. It is now
evident that acute myocardial infarction (AMI) refers to the
acute clinical symptoms and not necessarily to completely
acutely formed fresh thrombi.
In addition, the obstruction is not always a fully ﬁbrin-
based clot. The recognition of extracellular leukocyte net-
works with nucleotide strands in ﬁbrin clots implies the need
of DNA-ase to contribute to the lysis of such networks.3–5
These reﬁnements in knowledge of the target thrombus,
mainly established for AMI, might provide clues for the
observed apparent ceiling in recanalization rate (around
80–90%) that can be achieved by lysis strategies6 and count
in favor of mechanical methods which can achieve higher
patency rates.
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► bleeding risk
Abstract Thrombolytic therapy involves thrombolytic agents administered to patients suffering
from venous or arterial thrombosis. The therapy induces systemic effects interrelated
with the thrombolytic agent used. Bleeding is a prominent complication of thrombolytic
therapy. Exhaustion of coagulation factors, generation of excessive amounts of ﬁbrin
degradation products (FDPs), therapy-induced activation of coagulation, therapy-
induced anticoagulation, and formation of new ﬁbrin all illustrate the complexity of
effects of the treatment and challenges the hemostatic balance in the patients. The
therapy-induced effects can be modulated by parallel administration of anticoagulants.
Risk assessment is mandatory prior to thrombolytic therapy. Anticoagulated and
unconscious patients represent particular safety concerns, and should be fully evaluat-
ed. Several guidelines describe the choice of tests and their safety limits in relation to
pretreatment evaluation of anticoagulated patients. Fibrinogen depletion and FDPs
during treatment may be promising markers for the evaluation of bleeding risk
posttreatment. Future risk assessment measures should focus on the dynamics of
the hemostatic balance. Here, thromboelastography may be considered a tool address-
ing clot formation, ﬁbrin structure, and ﬁbrinolytic resistance in parallel. Suitable
laboratory analysis performed shortly after treatment may help to recognize severe
treatment-induced systemic effects that can be counteracted by rational treatment,
thereby reducing bleeding risk.
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Related to the above-mentioned insights, in more recent
years the single biological treatment with the thrombolytics
for AMI has become less used and has been replaced to a large
extent by mechanical methods of percutaneous coronary
intervention (PCI), aspiration of thrombi, and combinations
of lysis and mechanical strategies.
The present review concerns the safety associated with
thrombolytics, used either alone or as treatment component.
We focus on AMI and stroke, but all thrombolytic treatments
have in common a depletion of internal hemostatic factors
(systemic effects), anticoagulation, and a risk of bleeding
associated with that systemic effect.
From evaluation of mechanisms and large interindividual
variability in treatment and systemic response, it is suggested
to select laboratory methods for the monitoring of systemic
effects and the consequences in hemostasis for individuals to
predict bleeding and importantly to rationally assist in man-
agement of bleeding, which irrevocably will affect a subset of
patients undergoing thrombolytic treatment.
Mechanisms of Thrombolytics
Thrombolytics that have frequently been studied comprise
alteplase (recombinant tissue-type plasminogen activator
[rt-PA]), urokinase (urinary-type plasminogen activator,
both in active and proform), reteplase (which is part of
tissue-type plasminogen activator [t-PA], K2P, with reduced
clearance rate), and tenecteplase (a geneticallymodiﬁed t-PA,
possessing improved ﬁbrin speciﬁcity and reduced inhibition
by plasminogen activator inhibitor).
It has been well recognized that rapid lysis of thrombi by
exogenously provided thrombolytics is a forced situation to
achieve rapid lysis. The dosages of thrombolytics used are
therefore very high comparedwith plasma levels of endogenous
plasminogen activators. One of the premises for the high dose is
that plasminogen activators incorporated into the thrombus
during thrombus formation are far more effective than plasmin-
ogen activators deployed after thrombus formation. Further-
more, a t-PA dose in the high range has been selected in practice
to be effective also with respect to older and organized clots.
The difference in concentration of lytic agents for endoge-
nous and exogenous lysis has been illustrated by in vitro
experiments showing that a 20 to 40 times higher concentra-
tion of t-PA is needed for exogenous lysis compared with
endogenous lysis.7,8 Accordingly, levels of t-PA during throm-
bolysis reach 1 to 2 µg/mL, while endogenous free active t-PA
in resting condition is around 1 ng/mL9 and reaches 10 ng/mL
extra t-PA in plasma after exhaustive exercise,10while locally
endothelial stimulation can deliver 2 to 4 ng/min  L tissue to
be incorporated in forming thrombi.11
Mechanisms of Systemic Effects
Systemic effects have various origins as depicted in►Fig. 1,12
and will be discussed here.
Systemic effects are mainly an issue of thrombolytic
treatment due to the very high dosages used, as discussed
earlier, where the ﬁbrin speciﬁcity is not maintained.
History documents that the thrombolysis originally
performed by predominantly streptokinase therapy was
accompanied by adverse effects, involving severe systemic
reductions of ﬁbrinogen, plasminogen, and plasmin inhib-
itor.13 The developments of newer thrombolytics were
largely focused on improving ﬁbrin speciﬁcity and reducing
systemic effects. The thrombolytic agent evaluated exten-
sively after streptokinase and urokinase was t-PA, and the
reduced systemic effects of t-PA have been convincingly
documented in the ﬁrst head-to-head comparisons of
streptokinase and t-PA.13 Treatment with t-PA induces
less proteolysis of ﬁbrinogen, factor VIII, and factor V
than induced by streptokinase.
Several aspects of the mechanisms of systemic effects
can be recognized. Plasminogen activationwithout ﬁbrin is
a well-known phenomenon for streptokinase, but also
for urokinase and prourokinase,14,15 while it is less so for
t-PA. The mutated t-PAs (reteplase and tenecteplase) show
further reduction in systemic effects. The bat vampire
plasminogen activator is reported to be the most favorable
in this respect.16 These effects are studied with puriﬁed
thrombolytics and components.17,18 In a plasma system,
the presence of stimulating factors such as ﬁbrin degrada-
tion products (FDPs) interferes with conclusions about
mechanisms.
Next to the speciﬁc characteristics of a thrombolytic, the
ﬁbrin-independent effect is also strongly dependent upon
dosages of the thrombolytics. Anno 2016, the systemic effect
with current treatments is still too large and undesired and
more ﬁbrin-speciﬁc agents remain desired.19,20
Fig. 1 Scheme of systemic effect origins. Systemic effects can be due
to effects of thrombolytics without ﬁbrin, effects stimulated by ﬁbrin
degradation products (FDPs) from the primary thrombus, and from
clots/ﬁbrin originating from reactive coagulation following
thrombolysis.12
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Fibrin Degradation Products’ Effects
The concentrations of FDPs and large soluble ﬁbrin polymers
are elevated in patients with acute thrombotic diseases.
However, already in normal individuals these factors are
present and constitute soluble stimulating factors for plas-
minogen activation by t-PA. This was elegantly demonstrated
by a chromogenic assay based on stimulation of t-PA activity
showing in normal volunteers a level of 3 µg ﬁbrinogen/
ﬁbrin equivalents/mL of “soluble ﬁbrin.”21 During thrombo-
lytic treatment, these levels can increase 5- to 10-fold and are
supposed to not represent the small primary thrombus as
main source.22 This latter assumption is based on calculations
of the size of thrombi and expected amounts of FDPs and on
experiments showing generation of FDPs upon incubating
plasma with a lytic agent, and provided evidence for “new”
FDP generated by an ongoing coagulation processes during
thrombolytic treatment.22 The stimulation is predominantly
from fragments containing D and E fragments (DDE),23which
are normally included in so-called D-dimer assays and in
assays employing the E-domain for catching or tagging.24,25
Major Effects and a Threshold
Very large off-target effects of plasmin can occur, and are due
to the situation that the inhibitory capacity for plasmin in
plasma is not sufﬁcient to achieve a rapid neutralization of all
plasmin that can be formed. The level of plasminogen is
around 2 µM in normal human plasma, while the level of
rapidly acting plasmin inhibitor (the plasminogen-binding
form) is only 0.7 µM.26 This rapid plasmin inhibitor exerts one
of the fastest biological interactions addressing non–ﬁbrin-
bound plasmin.27 After this very effective inhibitory barrier,
the inhibition by the non–plasminogen-binding plasmin
inhibitor (0.3 µM) and by α-2-macroglobulin (2 µM) is slower.
The slower inhibition allows plasmin, as broad-spectrum
protease, to also proteolyze other proteins more effectively.
In hemostasis, the well-known “victims” after ﬁbrinogen are
von Willebrand factor,28 factor VIII,29,30 and factor V and
Va,31–33 all shown to be sensitive to plasmin. Also factor IX
and factor X are plasmin sensitive,34,35 and to a minor extent
factor XIII.36–38 The formation of large ﬁbrin and ﬁbrinogen
degradation products with the capacity to stimulate in solu-
tion t-PA-induced plasminogen activation occurs predomi-
nantly after passing the highly effective inhibitory barrier of
plasminogen-binding plasmin inhibitor and can be counter-
acted by providing additional plasmin inhibitor.39
Itmaybe clear thatdegradationof clotting factors: (1) impairs
coagulation, (2) that formed ﬁbrin and ﬁbrinogen degradation
products that impair ﬁbrin polymerization and stimulate plas-
min formation in solution, and (3) that the exhaustion of
ﬁbrinolysis inhibitors facilitate lysis of clots. This renders sys-
temic effects an important determinant of the risk of bleeding. It
is of importance to recognize that systemic effects are quite
different among patients. Residual ﬁbrinogen analysis illustrates
this aspect clearly for t-PA treatment (see ►Fig. 213), demon-
strating residualﬁbrinogen concentrations in averybroad range.
It can be concluded that one important issue regarding
selection of improved thrombolytics is related to reduction of
systemic effects. In addition, variable susceptibility among
individuals may call for laboratory diagnostic testing to both
recognize susceptible patients and identify the actual con-
sequences of systemic adverse effects.
Evaluation of the Ratio between Thrombolysis and
Systemic Effects
In early phases of development of a new thrombolytic, its
dose-dependent efﬁcacy and side effects can be documented
in detail with specialized laboratory methods. This has been
done in the past for agents including streptokinase, APSAC
(anisoylated plasminogen streptokinase activator complex),
t-PA, urokinase prourokinase, reteplase, tenecteplase, des-
moteplase, and (micro)plasmin, and is still ongoing for new
agents and treatment modulation. Such a new agent is a
mutant of pro-u-PA which upon activation is speciﬁcally
more strongly inhibited by C1-inactivator, reducing its non-
ﬁbrin impact40. A treatment modality that mimics endoge-
nous synergy between t-PA and prourokinase using
combination treatment is also an option, although it is less
well explored, to increase ﬁbrin speciﬁcity.19
In Vitro Dose Finding
In vitro methods for efﬁcacy concern typically clot lysis tests
by an exogenously provided thrombolytic, involving, for
instance, hanging clot and Chandler loop principles.41,42
The methods for evaluation of side effects can be used in a
combination of the same tests by evaluation of non–clot-
bound actions in the surrounding blood or plasma. This can
also be done by incubation of plasma with the thrombolytic
agent. Such tests can include assays of plasminogen consump-
tion, residual rapid plasmin inhibitor, formation of plasmin–
plasmin inhibitor complexes, plasmin–α-2-macroglobulin
complexes, and formation of FDPs, and proteolysis of ﬁbrino-
gen to its Bβ 1–42 fragments and degradation/inactivation of
factor VIII, factor V, and vonWillebrand factor. An interesting
option arises from the availability of an assay speciﬁc to
ﬁbrinogen degradation products reporting off-target proteo-
lytic action of plasmin on ﬁbrinogen.24
The in vitro ratio ﬁbrin speciﬁcity/efﬁcacy and side effects
(systemic effects) can be documented for different dosages
Fig. 2 Categories of patients with different residual ﬁbrinogen after t-
PA treatment. Data taken from Collen et al.13
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and benchmarked with rt-PA. It can be used to support the
selection of dosages for treatment and positioning of the new
thrombolytic agent relative to existing ones.
In dose-ﬁnding studies in individuals, the same assays can
be applied for the systemic effects (provided the sample is
stabilizedwhen necessary by addition of inhibitors). It should
be noted, as discussed earlier, that laboratory studies on FDPs
for analysis of the lysis of pathological thrombi (unless
massive) are not options for efﬁcacy in patient treatment
(see discussion later). Here, recanalization and eventually
survival and risk of reinfarction are the relevant end points.
Dynamics of Lysis and Coagulation in the
Patients during Thrombolysis
Treatment-Induced New Fibrin Formation
Lysis of an occluding thrombus is expected to result in
reperfusion and in uncovering thrombogenic surfaces, and
potentially the thrombolytic is involved in removing hemo-
static ﬁbrin clots or counteracting new formation of hemo-
static clots. Activation of the coagulation mechanism not only
is plausible, but also has been documented to occur during
thrombolysis (see the discussion later). Accordingly, in vivo,
the lysis of the thrombus with a thrombolytic is not a linear
process of lysis, but involves also a feedback activation of
coagulation and formation of newclots. Thus, lysis has to cope
with existing and newly formed ﬁbrin due to the treatment.
This new coagulation effect can contribute to reocclusion and
eventually reduced efﬁcacy of the treatment. This dynamic
process of treatment-induced coagulation is well recognized
in MI (also coined as thrombolytic paradox) and is docu-
mented in animal models where experimental clots show
lysis and growth.43 Treatment-induced coagulation is also
documented in MI patients by the generation of coagulation
activation products such as prothrombin fragment 1 þ 2
(thrombin generationmarker), thrombin–antithrombin com-
plex (thrombin presence marker), and ﬁbrinopeptide A
(thrombin action marker). A consequence is that the concen-
tration of FDPs is much higher than can be expected from the
existing thrombus due to substantial contribution from the
additional lysis of the newly formed ﬁbrin. The treatment-
induced coagulation and the prothrombotic condition of the
infarcted area, in combination with the apparent prothrom-
botic phenotype of the infarct patient, can result in reocclu-
sion of the target vessel. The coagulation process involved can
be modulated by the use of inhibitors such as heparins and
platelet inhibitors, which are carefully selected and evaluated
for effect and steady companions in the thrombolytic treat-
ment ofMI and under investigation for stroke, and still subject
of research to improve effects.44 The treatment-induced
coagulation is related to the speciﬁc thrombolytic, the dosage,
and way of administration. As an example, this is illustrated
by differences in generated activation markers of coagulation
when comparing infusion and bolus (►Fig. 3).45,46
Modulation of Treatment-Induced Coagulation
Treatment-induced coagulation can be modulated by inhibi-
tion of coagulation in parallel with the administration of the
thrombolytic agent. Initially, heparin and/or antiplatelet
agents were used as modulators in patients with MI. Current
recommendations include adjuvant regimens with enoxa-
parin, unfractionated heparin (UFH), and fondaparinux.47
Evaluation of rt-PA combined with platelet glycoprotein
IIB–IIIA inhibitors is still under study for stroke.48,49
More recent approaches also include the possibilities of
the inhibition of contact activation, factor XI action, thrombin
inhibition, and TAFI (thrombin-activatable ﬁbrinolysis inhib-
itor) inhibition. It has been recognized that thrombus stabili-
zation follows activation of the intrinsic system (factor XII,
prekallikrein, and in particular factor XI), while the thrombin
formed by this route activates TAFI, which is an inhibitor of
ﬁbrinolysis and retards clot lysis.50 This is expected to have
Fig. 3 Molecular markers during and after treatment with bolus t-PA (four boluses in 1 hour) and infusion of t-PA for a total of 6.5 hours for
patients showing recanalization. Data are from the study of Andreotti et al,46 and medians and standard errors are plotted.
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contributed to stabilization of the culprit thrombus in infarct-
related areas and is operational indeed for the initial throm-
bus, as suggested by increases in factor XIa–C1-inactivator
complex51 and by the thrombotic effects in experimental
studies in factor XII– or prekallikrein-depletedmice, in case of
inhibitors of factor XIIa (mice and rat model),52 in case of
inhibition of factor XI in mice and rabbit models,53 and by
XIIa and XIa inhibition in extracorporeal circulation and
grafts.54,55
Speciﬁc options for modulation of treatment-induced
coagulation may be targeted at TAFI because of positive
reports showing that, in TAFI-deﬁcient mice, venous thrombi
are smaller and TAFI polymorphism inﬂuences stroke bur-
den.56 TAFI inhibition shows less microthrombosis57 and
ﬁbrin deposition in the lung in experimental models,58 and
it induces more lysis in a rabbit model51 and potentiates
jugular vein lysis.59
The occurrence of this mechanism of thrombus stabiliza-
tion via the intrinsic route is likely to operate also in the new
thrombolytic-induced coagulation. Some experimental
evidence is provided from increases during thrombolysis in
activated factor XII60,61 and in cleaved high-molecular-
weight kininogen.60,62,63 Interestingly long-lasting depletion
of the FXII-dependent pathway of ﬁbrinolysis has been
reported in patients undergoing thrombolytic therapy with
rt-PA, thereby carrying an increased risk of early reinfarc-
tion.64 More thorough documentation is warranted, and
based on such observations regarding the role of the contact
system and TAFI, new adjuvant treatment may arise in the
near future.65
A focusedway tomodulate treatment-induced coagulation
could be by inhibition of TAFI formation or TAFI directly.66,67
TAFI participation requires thrombomodulin, which will be a
major co-determinant. Inhibition of thrombin and subse-
quent TAFI formation by the use of argatroban indeed stim-
ulates lysis.68
Systemic Effects during Treatment
Of importance is that the systemic effects are stimulated by
lysis of the thrombus, which results in the formation of large
FDPs that show stimulatory action for t-PA.23 Paradoxically,
the larger the effects of the ﬁbrinolysis target (existing þ
newly formed thrombi), the larger the systemic effects may
become.
The systemic effects reduce the quality of newly formed
ﬁbrin clots by several mechanisms:
• The amount of ﬁbrinogen is reduced, whichmay result in a
smaller clot.
• Fibrin and ﬁbrinogen degradation products disturb ﬁbrin
polymerization and cause a change in ﬁbrin structure.69
• Reduced coagulation results in impaired cross-linking
(factor XIII) and reduced inhibitor formation (TAFI
activation).
In addition, the anticoagulant used to prevent reactive
coagulation during and after treatment adds to impairment
of coagulation activation and consequently the risk of
bleeding.
The complex situation in vivo during thrombolysis and the
application of different thrombolytics and regimen with
anticoagulation lead to a set of rules about systemic effects.
Reduced systemic effects link with:
• Inhibition of rethrombosis and reducing treatment-
induced clot formation
• Fibrin speciﬁcity of the lytic agent asmoreﬁbrin speciﬁcity
causes less systemic effect by ﬁbrin-independent effects,
by low circulating soluble ﬁbrin and by low large ﬁbrin
(ogen) breakdown products
Increased systemic effects link with:
• Larger thrombi and a strong prothrombotic phenotype of
the patient
• Higher dosage of a thrombolytic or prolonged infusion
schemes
• Coagulation inhibition targeting at the intrinsic pathway,
which gives more/faster lysis
Thus, treatment with thrombolytics requires strategies
reducing the treatment-induced activation of coagulation,
thereby further decreasing the bleeding risk. For assessment
of bleeding risk, two lines could be followed: (1) evaluation of
the patient before treatment for risk factors for bleeding and
(2) evaluation of the patient after completion of treatment for
risk of posttreatment bleeding.
Identiﬁcation of Patients for Thrombolysis:
Risk Assessment
Major bleeding is still a signiﬁcant problem of thrombolytic
therapy, despite the development of ﬁbrin-speciﬁc drugs. For
all thrombolytics available today, there are to a certain extent
systemic adverse effects of which hemorrhagic stroke is
considered the most feared complication. Thrombolytic
agents that are presently available do not have the capability
to distinguish between pathological thrombi and normal
hemostaticﬁbrin plugs. The riskof hemorrhagic stroke ranges
from 1 to 7% depending on the target organ of the thrombo-
lytic agent.70–72 The current scope for use of intravenous
thrombolytic agents is thrombotic stroke, STEMI (ST segment
elevation myocardial infarction), pulmonary embolism, and
to a lesser extent vein thrombosis. Because of the high
treatment-induced bleeding risk, major efforts should be
undertaken to exclude patients who have a higher risk for
bleeding. It should be noted that only alteplase is FDA
approved for thrombolysis of thrombotic stroke. Also, it
should be noted that the primary treatment of STEMI is
PCI and that thrombolytic treatment of non-STEMI is not
indicated.
The efforts to reduce the bleeding risk in thrombolytic
therapy have resulted in recommendations on absolute con-
traindications. Such recommendations are based on clinical
information or biochemical measures. ►Table 173 summa-
rizes the hemostasis contraindications.
Also, it is recommended to perform biochemical tests to
help guide whether the patients are eligible for thrombolytic
therapy (►Table 273).
Seminars in Thrombosis & Hemostasis Vol. 43 No. 3/2017
Safety of Thrombolysis Kluft et al.304
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 L
ib
ra
ry
 o
f S
ou
th
er
n 
De
nm
ar
k.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Laboratory Tests (Pretreatment)
Identiﬁcation of patients at risk of bleeding prior to throm-
bolytic therapy is mandatory to ensure the safety of the
treatment. Patients subjected to thrombolytic therapymostly
have a prothrombotic phenotype andwill not generally suffer
from inherited bleeding tendency, that is, coagulation factor
deﬁciencies and platelet disorders. The majority of patients,
however, may have an acquired bleeding risk due to antico-
agulant treatment, that is, heparins, vitamin K antagonists
(VKAs), and direct oral anticoagulants (DOACs; being direct
thrombin inhibitors [dabigatran, argatroban] and direct or
indirect inhibitors of FXa [rivaroxaban, apixaban, fondapar-
inux]). Particular problems are related to unconscious
patients who are possibly on treatment with DOACs, as tests
to exclude use of DOACs are not widely available in routine
laboratories. However, to ensure the safety of the treatment,
the laboratory analysis repertoire should identify these con-
ditions before thrombolytic therapy is initiated.
According to international guidelines, global tests such as
the prothrombin time (PT) and the activated partial pro-
thrombin time (aPTT) may be particularly useful for identiﬁ-
cation of patientswith increased riskof bleeding, while ruling
out patients receiving low-molecular-weight (LMW) heparin
and to some extent DOACs that require more speciﬁc
tests.73–75 Quick access to relevant laboratory results is
important for the visitation of patients for and on thrombo-
lytic therapy. Hence, point-of-care test (POCT) devices are
advantageous for laboratory testing in the thrombolytic
setting, because the turnaround time of the tests is short
and the analysis can be performed at bedside. Guidelines
focusing on the preanalytical and analytical conditions of the
assay procedures should be followed to ensure that the
outcome of the analytical work is reliable.75–77
Testing for Vitamin K Antagonists
The test of choice ruling out VKA treatment is the PT
addressing the coagulation capacity of the tissue factor–
induced (extrinsic) and common coagulation pathway. A
variety of PT assays and applications are available, and the
PT can be reliably performed using POCT devices.78,79 The
outcome of the analysis can be expressed in seconds, ratio,
and international normalized ratio (INR).80 Ischemic stroke
patients on VKA treatment with INR < 1.7 can safely be
treated with intravenous rt-PA.73,81,82 PT values below
15 seconds are also considered safe,73 but it should be noted
that the clotting time of the PT depends on the assay con-
ditions and the equipment used for analysis. Thus, a PT safety
limit expressed in seconds is not recommendable.
Testing for Heparins
The aPTT addresses the coagulation capacity of the surface-
induced (intrinsic) and common coagulation pathway. The
aPTT is sensitive to UFH. Only few POCT devices capable of
measuring aPTT are presently available83–85 and their perfor-
mance in a thrombolytic setting has not been evaluated so far.
The outcome of the aPTT can be expressed in seconds or ratio.
An aPTT ratio within the reference range of the assay prior to
thrombolysis is considered as safe,73whereas other guidelines
recommend a safety range of the aPTT ratio as  1.5 times the
baseline value.74 It is, however, not clear how this baseline
value is deﬁned. It should be noted that the aPTT is not suitable
for detection of LMW heparin or fondaparinux, which should
be determined with anti-FXa assays.75
Testing for Direct Oral Anticoagulants
Treatment with direct thrombin or FXa inhibitors may prolong
the PT and aPTT, but these measurements are not reliable for
measuring the pharmacokinetic or pharmacodynamic effects of
DOACs. The aPTT, however,maybeused to screen for presenceof
dabigatran and rivaroxaban, but the aPTT is unsuitable to
determine the concentration of the drugs. A normal aPTT cannot
exclude the presence of dabigatran in some patients, and both
the PT and aPTT are insensitive to apixaban.
The thrombin time (TT) and ecarin clotting time (ECT) are
both sensitive to the presence of direct thrombin inhibitors,
and normal clotting times with these tests suggest very low
plasma levels of these drugs. Studies have suggested using the
combination of TT and aPTT measurements as a safety indica-
tor prior to thrombolysis.86 It is, however, recommended that
dilute thrombin-based assays, ECT-based assays, or chromo-
genic anti-IIa assays should be used for determination of
Table 2 Biochemical measures to guide eligibility of patients
for thrombolytic therapy
Blood glucose
Oxygen saturation
Electrolytes/EGFR/creatinine
Complete blood count, including platelets
Prothrombin time (PT)
Activated partial thromboplastin time (aPTT)
Electrocardiography (ECG)
Troponins
Abbreviation: EGFR, estimated glomerular ﬁltration rate.
Source: adapted from Jauch et al.73
Table 1 Clinical information to decide eligibility of patients for
thrombolytic therapy
• Time from stroke symptoms  4.5 h
• Time from MI symptoms  24 h
• Previous intracranial hemorrhage or stroke of
unknown origin
• Blood pressure > 185/110 mm Hg after two attempts to
reduce blood pressure
• Active gastrointestinal bleeding within 1 mo
• Surgery and trauma within 14 d
• Noncompressible punctures within 24 h
(liver biopsy, etc.)
• Ischemic nerve system/neoplasms/known atrioventricular
malformation
• Current use of warfarin INR > 1.7
• Current use of direct thrombin or factor Xa
inhibitors (DOACs)
Abbreviations: DOACs, direct oral anticoagulants; INR, international
normalized ratio; MI, myocardial infarction.
Source: Adapted from Jauch et al.73
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dabigatran, whereas chromogenic anti-Xa assay should be
used for determination of direct Xa inhibitors such as rivarox-
aban. A variety of speciﬁc chromogenic anti-IIa and anti-Xa
assays are available for measurement of DOACs,83,87–92 and
several of these assays are available as POCT. It is of particular
note that all assays should be calibrated with drug-speciﬁc
calibrators. A thorough and comprehensive guideline describ-
ing themeasurement of DOACs has been published recently.75
Recent guidelines state that patients treated with DOACs
should not be subjected to thrombolytic therapy with rt-PA
unless the aPTT, PT, and platelet count are normal. Moreover,
safe treatment with rt-PA requires that the ECT, TT, or
appropriate direct FXa activity assays are normal, or that
the patient has not received a dose of DOACs for >2 days.73
This recommendation, however, is rather weak (class III; level
of evidence C) and further research is needed to consolidate
the safety limits of DOACs. The recommended tests and safety
limits in anticoagulated patients are listed in ►Table 3.
Thromboelastography (TEG) and rotational thromboelas-
tometry (ROTEM) are promising tools to investigate the
anticoagulant effect of DOAC as demonstrated by in vitro
studies,93 and the techniques can also be used for detection of
factor deﬁciencies, presence of heparins, and VKAs. Clinical
trials focusing on apixaban and rivaroxaban have shown that
TEG may be a suitable tool for the determination of DOACs,
also in the thrombolytic setting,94,95 but the precision of the
assays in some cases is poor.96 More studies are needed to
reach ﬁrm conclusions regarding the usage of TEG and
ROTEM in relation to thrombolytic risk assessment.
Laboratory Tests (Posttreatment)
Reduction in the plasma concentration of ﬁbrinogen after
thrombolytic therapy is signiﬁcantly associated with risk of
posttreatment bleeding.97–100 A large clinical trial with more
than 500 patients receiving rt-PA as thrombolytic agent
demonstrated that a reduction in ﬁbrinogen of  2 g/L
from baseline to 6 hours after therapy increased the risk of
bleeding in the ﬁrst 72 hours after therapy more than four
times, and that the negative predictive value of ﬁbrinogen
depletion for any major bleeding was 94%.97 Another study,
assessing the ﬁbrinogen concentration before and 2 hours
after rt-PA therapy, showed that a reduction in ﬁbrinogen
concentration of 25% or more during therapy, or a ﬁbrinogen
concentration  2 g/L after therapy increased the bleeding
risk in the ﬁrst week after therapy more than seven times.98
For comparison, a study of patients subjected to rt-PA
treatment due to peripheral arterial or venous thrombosis
showed that the rate of major bleeding was signiﬁcantly
higher for patients with a ﬁbrinogen level  1.5 g/L.99
These studies demonstrate that plasma ﬁbrinogen levels
may serve as a posttreatment safety indicator of thrombo-
lytic therapy.
Coinciding with a nadir in ﬁbrinogen, treatment of stroke
or MI with rt-PA showed a peak in FDPs between 1 and 4
hours.37,101 Sampling at 2 hours after start of treatment
showed a relationship of FDP level with hemorrhage in
several studies.101–104 High FDPs at 24 hours was suggested
as contraindication for antithrombotic drugs in the ﬁrst 72
hours after stroke.102 These studies demonstrate that FDPs
levels may also serve as a posttreatment safety indicator of
thrombolytic therapy. It is suggested to further invest in
comparisons of FDP assays in view of the data (see later)
that DDE containing fragments are more active in systemic
activation.
It should be noted that anticoagulant therapy, irrespective
of the drug used, should not be initiated in stroke patients
within 24 hours of treatment with intravenous rt-PA.73
Conclusion and Future Options
The bleeding diathesis in thrombolysis treatment shows
similarities with bleeding diathesis in traumatic and post-
surgery situations. ROTEM or TEG analyses have been used in
these settings, andmay also be promising tools for evaluation
of the coagulation status prior and after thrombolytic
therapy.
Table 3 Recommendations of choice of tests and safety limits in patients receiving anticoagulant treatment prior to thrombolytic
therapy
Drug Recommended test Safety limit
Vitamin K antagonists Prothrombin time INR < 1.7
PT < 15 s
Unfractionated heparin Activated partial thromboplastin time Values within reference range
aPTT < 1.5  baseline
LMW heparin Anti-Xa assay Not applied
Fondaparinux Anti-Xa assay Not applied
Direct thrombin inhibitors
Dabigatran
Argatroban
Thrombin time
Ecarin clotting time
Chromogenic anti-IIa assay
Values within reference ranges
Last dosage > 2 d ago
Direct factor Xa inhibitors
Rivaroxaban
Apixaban
Chromogenic anti-Xa assay Values within reference ranges
Last dosage > 2 d ago
Abbreviations: aPTT, activated partial thromboplastin time; INR, international normalized ratio; LMW, low molecular weight; PT, prothrombin time.
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These analyses, performed at bedside and using whole
blood, show sensitivity toward most coagulation disorders,
platelet dysfunction, and presence of various anticoagulants.
We have previously demonstrated that ROTEM analysis prior
to surgery is predictive of intraoperative bleeding in an
orthognathic setting.105
Evaluation of ﬁbrinogen turnover during thrombolytic
therapy may be another option ensuring the safety of treat-
ment. Patients depleted in ﬁbrinogen during surgery and
identiﬁed with ROTEM or TEG analyses could be supple-
mented with ﬁbrinogen to prevent postsurgical bleeding,
according to the most recent guidelines from the European
Society of Anaesthesiology.106 In contrast, a Cochrane Data-
base Systemic Review concludes that currently only weak
evidence supports the use of ﬁbrinogen concentrate in bleed-
ing patients, tested in primarily elective cardiac surgery, and
that more research is urgently needed.107
A further advancement may be the application after
thrombolysis of amethod incorporating data on ﬁbrin quality
and lysis susceptibility. A complex phenotypic test reﬂecting
all elements of risk of bleeding in thrombolysis patients—
reduced clotting, reduced elasticity, increased sensitivity to
lysis programmed by low thrombin formation, and reduced
TAFI activation—and the interrelations might be a rational,
theoretical choice. To that end, it is possible to select a ROTEM
variant in line with those proposed,108 with low clotting
stimulation (low tissue factor) to give way to expression of
the endogenous clotting status and to express effects of TAFI,
and to add t-PA to the test. It is suggested to explore this type
of approach and perform studies to evaluate its validity to
possibly reach high efﬁcacy in risk analysis.
References
1 Kramer MC, van der Wal AC, Koch KT, et al. Histopathological
features of aspirated thrombi after primary percutaneous
coronary intervention in patients with ST-elevation myocardial
infarction. PLoS ONE 2009;4(6):e5817
2 Rittersma SZ, van der Wal AC, Koch KT, et al. Plaque instability
frequently occurs days or weeks before occlusive coronary
thrombosis: a pathological thrombectomy study in primary
percutaneous coronary intervention. Circulation 2005;111(9):
1160–1165
3 Longstaff C, Varjú I, Sótonyi P, et al. Mechanical stability and
ﬁbrinolytic resistance of clots containing ﬁbrin, DNA, and histo-
nes. J Biol Chem 2013;288(10):6946–6956
4 Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood
2014;123(18):2768–2776
5 Oklu R, Albadawi H, Watkins MT, Monestier M, Sillesen M,
Wicky S. Detection of extracellular genomic DNA scaffold in
human thrombus: implications for the use of deoxyribonucle-
ase enzymes in thrombolysis. J Vasc Interv Radiol 2012;23(5):
712–718
6 Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improve-
ment guidelines for percutaneous catheter-directed intra-arterial
thrombolysis and mechanical thrombectomy for acute lower-limb
ischemia. Cardiovasc Intervent Radiol 2011;34(6):1123–1136
7 Brommer EJ. The level of extrinsic plasminogen activator (t-PA)
during clotting as a determinant of the rate of ﬁbrinolysis;
inefﬁciency of activators added afterwards. Thromb Res 1984;
34(2):109–115
8 Zamarron C, Lijnen HR, Collen D. Inﬂuence of exogenous and
endogenous tissue-type plasminogen activator on the lysability
of clots in a plasma milieu in vitro. Thromb Res 1984;35(3):
335–345
9 Kluft CMP, Ersdal E, Rosen S. Tissue-Type Plasminogen Activator
(t-PA) Activity. Dordrecht: Kluwer Academic Publisher; 1999
10 Hilberg T, Prasa D, Stürzebecher J, Gläser D, Schneider K, Gabriel
HH. Blood coagulation and ﬁbrinolysis after extreme short-term
exercise. Thromb Res 2003;109(5–6):271–277
11 Hrafnkelsdóttir T, Ottosson P, Gudnason T, Samuelsson O, Jern S.
Impaired endothelial release of tissue-type plasminogen activa-
tor in patients with chronic kidney disease and hypertension.
Hypertension 2004;44(3):300–304
12 Hoffmeister HM, Szabo S, Helber U, Seipel L. The thrombolytic
paradox. Thromb Res 2001;103(Suppl 1):S51–S55
13 Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M.
Analysis of coagulation and ﬁbrinolysis during intravenous infu-
sion of recombinant human tissue-type plasminogen activator in
patients with acute myocardial infarction. Circulation 1986;
73(3):511–517
14 Michels R, Hoffmann H,Windeler J, Barth H, Hopkins G. A double-
blind multicenter comparison of the efﬁcacy and safety of
saruplase and urokinase in the treatment of acute myocardial
infarction: Report of the sutami study group. J Thromb Throm-
bolysis 1995;2(2):117–124
15 Goto S, Kawai Y, Abe S, et al. Serial changes in coagulant activities
after thrombolytic therapy for acute myocardial infarction. Angi-
ology 1994;45(4):273–281
16 Gardell SJ, Ramjit DR, Stabilito II, et al. Effective thrombolysis
without marked plasminemia after bolus intravenous adminis-
tration of vampire bat salivary plasminogen activator in rabbits.
Circulation 1991;84(1):244–253
17 Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of
plasminogen by pro-urokinase. II. Kinetics. J Biol Chem 1986;
261(3):1259–1266
18 Zamarron C, Lijnen HR, Collen D. Kinetics of the activation of
plasminogen by natural and recombinant tissue-type plasmino-
gen activator. J Biol Chem 1984;259(4):2080–2083
19 Gurewich V. Why so little progress in therapeutic thrombolysis?
The current state of the art and prospects for improvement.
J Thromb Thrombolysis 2015;40(4):480–487
20 Weitz JI. Limited ﬁbrin speciﬁcity of tissue-type plasminogen
activator and its potential link to bleeding. J Vasc Interv Radiol
1995;6(6, Pt 2, Suppl):19S–23S
21 WimanB, RånbyM.Determination of solubleﬁbrin in plasma bya
rapid and quantitative spectrophotometric assay. Thromb Hae-
most 1986;55(2):189–193
22 Francis CW, Kornberg A. Fibrinogen- and ﬁbrin-degradation
products during ﬁbrinolytic therapy. Ann N Y Acad Sci 1992;
667:310–323
23 Weitz JI, Leslie B, Ginsberg J. Soluble ﬁbrin degradation products
potentiate tissue plasminogen activator-induced ﬁbrinogen pro-
teolysis. J Clin Invest 1991;87(3):1082–1090
24 Koppert PW, Kuipers W, Hoegee-de Nobel B, Brommer EJ, Koop-
man J, Nieuwenhuizen W. A quantitative enzyme immunoassay
for primary ﬁbrinogenolysis products in plasma. Thromb Hae-
most 1987;57(1):25–28
25 Soria J, Soria C, Mirshahi M, et al. A speciﬁc marker of thrombolysis:
DDE complex [in French]. C R Acad Sci III 1987;304(11):307–311
26 Kluft C, Los P, Jie AF, et al. The mutual relationship between the
two molecular forms of the major ﬁbrinolysis inhibitor alpha-2-
antiplasmin in blood. Blood 1986;67(3):616–622
27 Wiman B, Collen D. On the kinetics of the reaction between
human antiplasmin and plasmin. Eur J Biochem 1978;84(2):
573–578
28 Hamilton KK, Fretto LJ, Grierson DS, McKee PA. Effects of plasmin
on von Willebrand factor multimers. Degradation in vitro and
stimulation of release in vivo. J Clin Invest 1985;76(1):261–270
Seminars in Thrombosis & Hemostasis Vol. 43 No. 3/2017
Safety of Thrombolysis Kluft et al. 307
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 L
ib
ra
ry
 o
f S
ou
th
er
n 
De
nm
ar
k.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
29 Holmberg L, Ljung R, Nilsson IM. The effects of plasmin and
protein Ca on factor VIII:C and VIII:CAg. Thromb Res 1983;31(1):
41–50
30 Nogami K, Shima M, Matsumoto T, Nishiya K, Tanaka I, Yoshioka
A. Mechanisms of plasmin-catalyzed inactivation of factor VIII: a
crucial role for proteolytic cleavage at Arg336 responsible for
plasmin-catalyzed factor VIII inactivation. J Biol Chem 2007;
282(8):5287–5295
31 Tracy RP, Rubin DZ, Mann KG, et al. Thrombolytic therapy and
proteolysis of factor V. J Am Coll Cardiol 1997;30(3):716–724
32 Omar MN, Mann KG. Inactivation of factor Va by plasmin. J Biol
Chem 1987;262(20):9750–9755
33 Kalafatis M, Mann KG. The role of the membrane in the inactiva-
tion of factor va by plasmin. Amino acid region 307-348 of
factor V plays a critical role in factor Va cofactor function. J Biol
Chem 2001;276(21):18614–18623
34 Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR. Proteo-
lytic processing of human coagulation factor IX by plasmin. Blood
2000;95(3):943–951
35 Pryzdial EL, Lavigne N, Dupuis N, Kessler GE. Plasmin converts
factor X from coagulation zymogen to ﬁbrinolysis cofactor. J Biol
Chem 1999;274(13):8500–8505
36 Cocho D, Borrell M, Martí-Fàbregas J, et al. Pretreatment hemo-
static markers of symptomatic intracerebral hemorrhage in
patients treated with tissue plasminogen activator. Stroke
2006;37(4):996–999
37 Sun X, Berthiller J, Derex L, Trouillas P, Diallo L, Hanss M. Post-
thrombolysis haemostasis changes after rt-PA treatment in acute
cerebral infarct. Correlations with cardioembolic aetiology and
outcome. J Neurol Sci 2015;349(1–2):77–83
38 Martí-Fàbregas J, Borrell M, Cocho D, et al. Hemostatic markers
of recanalization in patients with ischemic stroke treated with
rt-PA. Neurology 2005;65(3):366–370
39 Weitz JI, Leslie B, Hirsh J, Klement P. Alpha 2-antiplasmin
supplementation inhibits tissue plasminogen activator-induced
ﬁbrinogenolysis and bleeding with little effect on thrombolysis.
J Clin Invest 1993;91(4):1343–1350
40 Gurewich V, Pannell R. Recombinant human C1-inhibitor pre-
vents non-speciﬁc proteolysis by mutant pro-urokinase during
optimal ﬁbrinolysis. Thromb Haemost 2009;102(2):279–286
41 Korninger C, Collen D. Studies on the speciﬁc ﬁbrinolytic effect of
human extrinsic (tissue-type) plasminogen activator in human
blood and in various animal species in vitro. Thromb Haemost
1981;46(2):561–565
42 Mutch NJ, Moore NR, Mattsson C, Jonasson H, Green AR, Booth
NA. The use of the Chandler loop to examine the interaction
potential of NXY-059 on the thrombolytic properties of rtPA on
human thrombi in vitro. Br J Pharmacol 2008;153(1):124–131
43 Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct
dose-dependent effects of plasmin and TPA on coagulation and
hemorrhage. Blood 2003;101(8):3002–3007
44 Pettigrew LC, Dobbs MR. Stroke: thrombolysis and antithrom-
botic therapy. In: D. J. Moliterno, S. D. Kristensen, R. De Caterina
eds. Therapeutic Advances in Thrombosis, 2nd ed. Oxford, UK:
Blackwell Publishing Ltd; 2012
45 Andreotti F, Kluft C, Hackett DR, Davies GJ, Maseri A. Thrombin
generation after fast or prolonged regimens of tissue-type plas-
minogen activator. Lancet 1993;342(8876):937–938
46 Andreotti F, Kluft C, Davies GJ, Hackett DR, Prevost R, Maseri A.
Prolonged coagulation instability is associatedwith a higher-dose
regimen of tissue-type plasminogen activator in patients with
acutemyocardial infarction. Ann N YAcad Sci 1992;667:450–453
47 Sánchez PL, Fernández-Avilés F. An integrated approach to the
management of patients after the early phase of ST segment
elevation myocardial infarction. In: S Yusuf, JA Cairns, AJ Camm,
EL Fallen, BJ Gersh. Evidence-Based Cardiology, 3rd ed. Oxford,
UK: Wiley-Blackwell; 2009
48 Adeoye O, Sucharew H, Khoury J, et al. Combined approach to
lysis utilizing eptiﬁbatide and recombinant tissue-type plasmin-
ogen activator in acute ischemic stroke-full dose regimen stroke
trial. Stroke 2015;46(9):2529–2533
49 Pancioli AM, Adeoye O, Schmit PA, et al; CLEAR-ER Investigators.
Combined approach to lysis utilizing eptiﬁbatide and recombi-
nant tissue plasminogen activator in acute ischemic stroke-
enhanced regimen stroke trial. Stroke 2013;44(9):2381–2387
50 Bouma BN, Meijers JC. Thrombin-activatable ﬁbrinolysis inhibi-
tor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R,
procarboxypeptidase u). J Thrombosis Haemostasis 2003;1(7):
1566–1574
51 Minnema MC, Peters RJ, de Winter R, et al. Activation of clotting
factors XI and IX in patients with acute myocardial infarction.
Arterioscler Thromb Vasc Biol 2000;20(11):2489–2493
52 Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor
recombinant human albumin Infestin-4 abolishes occlusive arte-
rial thrombus formation without affecting bleeding. Circulation
2010;121(13):1510–1517
53 Leung PY, Hurst S, Berny-Lang MA, et al. Inhibition of factor xii-
mediated activation of factor xi provides protection against
experimental acute ischemic stroke in mice. Transl Stroke Res
2012;3(3):381–389
54 Schmaier AH. Extracorporeal circulation without bleeding. Sci
Transl Med 2014;6(222):222fs7
55 Tucker EI,Marzec UM,White TC, et al. Prevention of vascular graft
occlusion and thrombus-associated thrombin generation by in-
hibition of factor XI. Blood 2009;113(4):936–944
56 Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, et al. Inﬂuence of
thrombin-activatable ﬁbrinolysis inhibitor and plasminogen
activator inhibitor-1 gene polymorphisms on tissue-type plas-
minogen activator-induced recanalization in ischemic stroke
patients. J Thromb Haemost 2007;5(9):1862–1868
57 Sasaki T, Yoshimoto N, Sugimoto K, et al. Intravenous and oral
administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic
acid] produce thrombolysis through inhibition of plasma TAFIa in
rats with tissue factor-induced microthrombosis. Thromb Res
2012;130(4):e222–e228
58 Hendrickx ML, Zatloukalova M, Hassanzadeh-Ghassabeh G,
Muyldermans S, Gils A, Declerck PJ. In vitro and in vivo charac-
terisation of the proﬁbrinolytic effect of an inhibitory anti-rat
TAFI nanobody. Thromb Haemost 2014;111(5):824–832
59 Nagashima M,Werner M, WangM, et al. An inhibitor of activated
thrombin-activatable ﬁbrinolysis inhibitor potentiates tissue-
type plasminogen activator-induced thrombolysis in a rabbit
jugular vein thrombolysis model. Thromb Res 2000;98(4):
333–342
60 Merlini PA, Cugno M, Rossi ML, et al. Activation of the contact
system and inﬂammation after thrombolytic therapy in patients
with acute myocardial infarction. Am J Cardiol 2004;93(7):
822–825
61 Pönitz V, Pritchard D, Grundt H, Nilsen DW. Speciﬁc types of
activated factor XII increase following thrombolytic therapywith
tenecteplase. J Thromb Thrombolysis 2006;22(3):199–203
62 Agostoni A, Gardinali M, Frangi D, et al. Activation of complement
and kinin systems after thrombolytic therapy in patients with
acute myocardial infarction. A comparison between streptoki-
nase and recombinant tissue-type plasminogen activator. Circu-
lation 1994;90(6):2666–2670
63 Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact
system in response to pharmacological thrombolysis. Circulation
1995;91(1):28–36
64 Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor
XII-dependent ﬁbrinolytic activity characterizes patients with
early myocardial reinfarction after recombinant tissue-type
plasminogen activator therapy. J Am Coll Cardiol 1991;18(2):
454–458
Seminars in Thrombosis & Hemostasis Vol. 43 No. 3/2017
Safety of Thrombolysis Kluft et al.308
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 L
ib
ra
ry
 o
f S
ou
th
er
n 
De
nm
ar
k.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
65 Müller F, Gailani D, Renné T. Factor XI and XII as antithrombotic
targets. Curr Opin Hematol 2011;18(5):349–355
66 Klement P, Liao P, Bajzar L. A novel approach to arterial throm-
bolysis. Blood 1999;94(8):2735–2743
67 Vercauteren E, Gils A, Declerck PJ. Thrombin activatable ﬁbrino-
lysis inhibitor: a putative target to enhance ﬁbrinolysis. Semin
Thromb Hemost 2013;39(4):365–372
68 Hashimoto M, Yamashita T, Oiwa K, Watanabe S, Giddings JC,
Yamamoto J. Enhancement of endogenous plasminogen activa-
tor-induced thrombolysis by argatroban and APC and its control
by TAFI, measured in an arterial thrombolysis model in vivo using
rat mesenteric arterioles. Thromb Haemost 2002;87(1):110–113
69 Williams JE, Hantgan RR, Hermans J, McDonagh J. Characteriza-
tion of the inhibition of ﬁbrin assembly by ﬁbrinogen fragment D.
Biochem J 1981;197(3):661–668
70 Huynh T, Cox JL, Massel D, et al; FASTRAK II Network. Predictors
of intracranial hemorrhage with ﬁbrinolytic therapy in unselect-
ed community patients: a report from the FASTRAK II project. Am
Heart J 2004;148(1):86–91
71 Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major
hemorrhage following ﬁbrinolysis for acute pulmonary embo-
lism. Am J Cardiol 2006;97(1):127–129
72 Emberson J, Lees KR, Lyden P, et al; Stroke Thrombolysis Trialists’
Collaborative Group. Effect of treatment delay, age, and stroke
severity on the effects of intravenous thrombolysis with alteplase
for acute ischaemic stroke: a meta-analysis of individual patient
data from randomised trials. Lancet 2014;384(9958):1929–1935
73 Jauch EC, Saver JL, Adams HP Jr, et al; American Heart Association
Stroke Council; Council on Cardiovascular Nursing; Council on
Peripheral Vascular Disease; Council on Clinical Cardiology.
Guidelines for the early management of patients with acute
ischemic stroke: a guideline for healthcare professionals from
the American Heart Association/American Stroke Association.
Stroke 2013;44(3):870–947
74 Minematsu K, Toyoda K, Hirano T, et al; Japan Stroke Society.
Guidelines for the intravenous application of recombinant
tissue-type plasminogen activator (alteplase), the second edi-
tion, October 2012: a guideline from the Japan Stroke Society.
J Stroke Cerebrovasc Dis 2013;22(5):571–600
75 Kitchen S, Gray E, Mackie I, Baglin T, Makris M; BCSH committee.
Measurement of non-coumarin anticoagulants and their effects
on tests of haemostasis: guidance from the British Committee for
Standards in Haematology. Br J Haematol 2014;166(6):830–841
76 Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M; British
Committee for Standards in Haematology. Guidelines on the
laboratory aspects of assays used in haemostasis and thrombosis.
Int J Lab Hematol 2013;35(1):1–13
77 CLSI. Collection, Transport, and Processing of Blood Specimens for
Testing Plasma-Based Coagulation Assays and Molecular Hemo-
stasis Assays; Approved Guideline. 5th ed. CLSI Document h21-
a5. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
78 DrescherMJ, SpenceA, Rockwell D, Staff I, Smally AJ. Point-of-care
testing for coagulation studies in a stroke protocol: a time-saving
innovation. Am J Emerg Med 2011;29(1):82–85
79 Poller L, Keown M, Chauhan N, et al; ECCA Steering Group
Members. European Concerted Action on Anticoagulation. Cor-
rection of displayed international normalized ratio on two point-
of-care test whole-blood prothrombin time monitors (Coagu-
Chek Mini and TAS PT-NC) by independent international sensi-
tivity index calibration. Br J Haematol 2003;122(6):944–949
80 Poller L. International Normalized Ratios (INR): the ﬁrst 20 years.
J Thromb Haemost 2004;2(6):849–860
81 Mazya MV, Lees KR, Markus R, et al; Safe Implementation of
Thrombolysis in Stroke Investigators. Safety of intravenous
thrombolysis for ischemic stroke in patients treated with warfa-
rin. Ann Neurol 2013;74(2):266–274
82 Nilsson JB, Boman K, Jansson JH, Nilsson T, Näslund U. The
inﬂuence of acute-phase levels of haemostatic factors on reper-
fusion andmortality in patients with acute myocardial infarction
treated with streptokinase. J Thromb Thrombolysis 2008;26;
(3):188–195
83 Mani H, Herth N, Kasper A, et al. Point-of-care coagulation testing
for assessment of the pharmacodynamic anticoagulant effect of
direct oral anticoagulant. Ther Drug Monit 2014;36(5):624–631
84 Diener HC, Foerch C, Riess H, Röther J, Schroth G, Weber R.
Treatment of acute ischaemic strokewith thrombolysis or throm-
bectomy in patients receiving anti-thrombotic treatment. Lancet
Neurol 2013;12(7):677–688
85 Tan K, Booth D, Newell SJ, Dear PR, Hughes C, Richards M. Point-
of-care testing of neonatal coagulation. Clin Lab Haematol 2006;
28(2):117–121
86 Kate M, Szkotak A, Witt A, Shuaib A, Butcher K. Proposed
approach to thrombolysis in dabigatran-treated patients present-
ing with ischemic stroke. J Stroke Cerebrovasc Dis 2014;23(6):
1351–1355
87 De Luca R, Fontana P, Poncet A, de Moerloose P, Pﬁster RE.
Evaluation of theGEM®PCL Plus point-of-care device for neonatal
coagulation assessment: an observational study on cord blood.
Thromb Res 2014;134(2):474–478
88 Du S, Harenberg J, Krämer S, Krämer R, Wehling M, Weiss C.
Measurement of non-vitamin k antagonist oral anticoagulants in
patient plasma using heptest-stat coagulationmethod. Ther Drug
Monit 2015;37(3):375–380
89 Ebner M, Peter A, Spencer C, et al. Point-of-care testing of
coagulation in patients treated with non-vitamin k antagonist
oral anticoagulants. Stroke 2015;46(10):2741–2747
90 Harenberg J, Du S, Krämer S, et al. Novel methods for assessing
oral direct factor Xa and thrombin inhibitors: use of point-of-care
testing and urine samples. Semin Thromb Hemost 2013;39(1):
66–71
91 Harenberg J, Du S, Wehling M, et al. Measurement of dabigatran,
rivaroxaban and apixaban in samples of plasma, serum and urine,
under real life conditions. An international study. Clin Chem Lab
Med 2016;54(2):275–283
92 Shepherd MF, Jacobsen JM, Rosborough TK. Argatroban therapy
using enzymatic anti-factor IIa monitoring. Ann Pharmacother
2011;45(3):422–423
93 Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA,
Omert LA. Use of thromboelastography (teg) for detection of
new oral anticoagulants. Arch Pathol Lab Med 2015;139(5):
665–673
94 Bowry R, Fraser S, Archeval-Lao JM, et al. Thrombelastography
detects the anticoagulant effect of rivaroxaban in patients with
stroke. Stroke 2014;45(3):880–883
95 Adelmann D, Wiegele M, Wohlgemuth RK, et al. Measuring the
activity of apixaban and rivaroxaban with rotational thrombe-
lastometry. Thromb Res 2014;134(4):918–923
96 Kitchen DP, Kitchen S, Jennings I, Woods T, Walker I. Quality
assurance and quality control of thrombelastography and rota-
tional Thromboelastometry: the UK NEQAS for blood coagulation
experience. Semin Thromb Hemost 2010;36(7):757–763
97 Matosevic B, Knoﬂach M, Werner P, et al. Fibrinogen degradation
coagulopathy and bleeding complications after stroke thrombol-
ysis. Neurology 2013;80(13):1216–1224
98 Vandelli L,MariettaM, GambiniM, et al. Fibrinogen decrease after
intravenous thrombolysis in ischemic stroke patients is a risk
factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis
2015;24(2):394–400
99 Skeik N, Gits CC, Ehrenwald E, Cragg AH. Fibrinogen level as a
surrogate for the outcome of thrombolytic therapy using tissue
plasminogen activator for acute lower extremity intravascular
thrombosis. Vasc Endovascular Surg 2013;47(7):519–523
100 Saito M, Nakabayashi T, Iuchi K, et al. Effects of direct percutane-
ous transluminal coronary angioplasty treatment of acute myo-
cardial infarction onplasma levels of haemostatic and ﬁbrinolytic
factors. Blood Coagul Fibrinolysis 1993;4(5):801–804
Seminars in Thrombosis & Hemostasis Vol. 43 No. 3/2017
Safety of Thrombolysis Kluft et al. 309
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 L
ib
ra
ry
 o
f S
ou
th
er
n 
De
nm
ar
k.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
101 Ho CH, Wang SP. Serial thrombolysis-related changes after
thrombolytic therapywith TPA in patients with acutemyocardial
infarction. Thromb Res 1990;58(3):331–341
102 Trouillas P, Derex L, Philippeau F, et al. Early ﬁbrinogen degrada-
tion coagulopathy is predictive of parenchymal hematomas in
cerebral rt-PA thrombolysis: a study of 157 cases. Stroke 2004;
35(6):1323–1328
103 MengR, Ji X, Li B, Zhou J, LiW, Ding Y. Dynamical levels of plasma F
(1þ2) and D-dimer in patients with acute cerebral infarction
during intravenous urokinase thrombolysis. Neurol Res 2009;
31(4):367–370
104 Ueda T, Hatakeyama T, Sakaki S, Ohta S, Kumon Y, Uraoka T.
Changes in coagulation and ﬁbrinolytic system after local intra-
arterial thrombolysis for acute ischemic stroke. Neurol Med Chir
(Tokyo) 1995;35(3):136–143
105 MadsenDE, Ingerslev J, Sidelmann JJ, Thorn JJ, Gram J. Intraoperative
blood loss during orthognathic surgery is predicted by thromboe-
lastography. J Oral Maxillofac Surg 2012;70(10):e547–e552
106 Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of
severe perioperativebleeding: guidelines from the European Society
of Anaesthesiology. Eur J Anaesthesiol 2013;30(6):270–382
107 Wikkelsø A, Lunde J, Johansen M, et al. Fibrinogen concentrate in
bleeding patients. Cochrane Database Syst Rev 2013;8:CD008864
108 Larsen OH, Fenger-Eriksen C, Ingerslev J, Sørensen B. Improved
point-of-care identiﬁcation of hyperﬁbrinolysis is needed.
Thromb Res 2012;130(4):690–691
Seminars in Thrombosis & Hemostasis Vol. 43 No. 3/2017
Safety of Thrombolysis Kluft et al.310
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 L
ib
ra
ry
 o
f S
ou
th
er
n 
De
nm
ar
k.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
